BIG
VKTX icon

Brooklyn Investment Group’s Viking Therapeutics VKTX Stock Holding History

Brooklyn Investment Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,088
Closed -$477K – 2025
2025
Q4 		$477K Buy
+13,088
New +$464K 0.02% 698
2025
Q3 		– Sell
-446
Closed -$11.8K – 2624
2025
Q2 		$11.8K Buy
446
+68
+18% +$1.79K ﹤0.01% 2090
2025
Q1 		$9.13K Buy
+378
New +$11.9K ﹤0.01% 1553

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Brooklyn Investment Group's VKTX Position: Q1 2026 in Review

Brooklyn Investment Group sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 13,088 shares — an estimated $477K sold.

Brooklyn Investment Group first reported a position in VKTX in Q1 2025 and held it in 3 quarters. The position peaked at $477K in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Brooklyn Investment Group reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brooklyn Investment Group sold 13,088 Viking Therapeutics shares in Q1 2026, an estimated $477K.
  • Brooklyn Investment Group first reported a position in Viking Therapeutics in Q1 2025 and held it in 3 quarters.
  • Brooklyn Investment Group's Viking Therapeutics position peaked at $477K in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.